[Appropriate intravesical retention time of @entity7765 concentration based on its level in @entity5 tissue, anti- XXXX effect and side effect in intravesical instillation therapy for @entity150 ].

@entity1 @entity7765 @entity7312 @entity5 @entity150
The present study was designed to investigate the appropriate intravesical retention time of @entity7765 ( @entity7312 ) for the treatment of @entity150 in terms of its anti- @entity5 effect and side effect. We administered @entity7312 to 22 @entity1 with superficial @entity150 intravesically and measured the @entity7312 concentration in the @entity5 tissues. @entity1 were divided into 3 groups by retention time; 8 for 30 minutes, 8 for 1 hour and 7 for 2 hours. Tumor tissues were obtained by transurethral resection 30 min., 1 or 2 hours after the intravesical instillation of @entity7312 at the fixed concentrations of 30 mg/30 ml. There was no significant difference in @entity7312 concentration between 3 groups. This indicates that the anti- @entity5 effect of intravesical instillation of the @entity7312 would be expected by only 30 min. of intravesical retention time at the @entity7312 concentration of 30 mg/30 ml. Then, we administered 30 mg/30 ml of @entity7312 solution for 30 min. to 10 @entity1 intravesically 6 times every 48 hours to investigate its clinical anti- @entity5 effect and side effect. There were 2 complete responses, 3 partial responses and 5 cases with no changes for a total response rate of 50%. No side effect was observed. It is considered that 30 min. of intravesical retention time at the @entity7312 concentration of 30 mg/30 ml would be appropriate in terms of its anti- @entity5 effect and side effect.
